Thread Rating:
  • 1 Vote(s) - 5 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Great news and a quick cure for joke
(03-22-2020, 12:52 AM)Ninurta Wrote: Well!

We didn't see this coming, now did we?

Quote:US drugmaker doubled price on potential coronavirus treatment


Have to buy subscription to read it, but the headline says all we need to know.  Right... no surprise there.

I think I may just do what others are doing and take some MMS. People have been taking for years and years with no problems as long as it taken properly.
(03-22-2020, 01:43 AM)Mystic Wanderer Wrote: Have to buy subscription to read it, but the headline says all we need to know.  Right... no surprise there.

Quote:Drugmaker Doubled Price on Possible Virus Treatment
March 19, 2020

“The only U.S. drugmaker that makes a potential treatment for the coronavirus that was touted by
President Trump raised the price by almost 100 per cent in January, as the virus caused havoc
across China,” the Financial Times reports.

“Rising Pharmaceuticals, a New Jersey based company, increased the price of chloroquine -an
antimalarial, which is one of the drugs that is being tested against Covid-19 -on January 23,
according to data from research firm Elsevier.”...'
[Image: attachment.php?aid=953]
If anyone has nothing else to do they can read  this report about the cure as published by the WHO link
(03-22-2020, 11:28 AM)Wallfire Wrote: If anyone has nothing else to do they can read  this report about the cure as published by the WHO link

"...Symptoms of COVID-19 are non-specific and the disease presentation can range from no symptoms
(asymptomatic) to severe pneumonia and death.

As of 20 February 2020 and 12 based on 55924 laboratory confirmed cases, typical signs and symptoms
include: fever (87.9%), dry cough (67.7%), fatigue (38.1%), sputum production (33.4%), shortness of breath
(18.6%), sore throat (13.9%), headache (13.6%), myalgia or arthralgia (14.8%), chills (11.4%), nausea or
vomiting (5.0%), nasal congestion (4.8%), diarrhea (3.7%), and hemoptysis (0.9%),
and conjunctival congestion (0.8%).

People with COVID-19 generally develop signs and symptoms, including mild respiratory symptoms and fever,
on an average of 5-6 days after infection (mean incubation period 5-6 days, range 1-14 days).

Most people infected with COVID-19 virus have mild disease and recover. Approximately 80% of laboratory
confirmed patients have had mild to moderate disease, which includes non-pneumonia and pneumonia cases,
13.8% have severe disease (dyspnea, respiratory frequency ≥30/minute, blood oxygen saturation ≤93%,
PaO2/FiO2 ratio <300, and/or lung infiltrates >50% of the lung field within 24-48 hours) and 6.1% are critical
(respiratoryfailure, septic shock, and/or multiple organ dysfunction/failure).

Asymptomatic infection has been reported, but the majority of the relatively rare cases who are asymptomatic on
the date of identification/report went on to develop disease. The proportion of truly asymptomatic infections is
unclear but appears to be relatively rare and does not appear to be a major driver of transmission.

Individuals at highest risk for severe disease and death include people aged over 60 years and those with
underlying conditions such as hypertension, diabetes, cardiovascular disease, chronic respiratory disease
and cancer.

Disease in children appears to be relatively rare and mild with approximately 2.4% of the total reported cases
reported amongst individuals aged under 19 years. A very small proportion of those aged under 19 years have
developed severe (2.5%) or critical disease (0.2%)..."

If one reads that from Wallfire's link, this is one weak-assed disease. Smoke 40 Capstan Full-Strength a day for
forty years and you get the same! However, I couldn't see a cure on that pdf, just how to avoid getting this flu.
[Image: attachment.php?aid=953]
I also found this, this is a very old drug that all side affects are known, and also its cheep. Why is there so much resistance to using it? it cant do any harm and seems to help, but then it is cheep. Think of all the money been made supplying equipment and making a vaccine. This drug could also have another affect, help to stop people getting the virus

Quote:The Hvidovre Hospital in Denmark also intends to test treating covid-19 with the malaria drug chloroquine.

Previously, Norwegian hospitals, for example, have expressed a desire to treat patients infected with the new coronavirus with malaria medication.
The message from the hospital on the outskirts of Copenhagen comes despite the fact that the Danish Medicines Agency, the Danish counterpart to the Swedish Medicines Agency, has distanced itself from the treatment. The authority believes that there is still no scientific evidence that chloroquine would have an effect on the new corona virus.
However, the hospital's physician Stig Eärt believes there are reasons to test the drug.
- Earlier findings indicate that it has had an effect on the corona virus in the way it shortened the course of the disease and made it less serious, he says to Danish TV2, citing French studies.
The ambition of the hospital is to also provide chloroquine to corona-infected patients' close relatives, to see if the drug can have preventative effects that can prevent the spread of infection.
News from Finland

Quote:A breakthrough in a Turku-based pharmaceutical company can bring relief to its corona pandemic

Anna Egutkina
1 hour ago


[Image: BB11gfEC.img?h=450&w=799&m=6&q=60&o=f&l=f]© Edited by MTV
A Finnish drug project is believed to help with coronavirus lung disease by restoring capillary integrity.

Yle uutiso i today the Turku-based drug company Faron Pharmaceuticals developed Traumakine-drug, that arouses intense interest, especially now, because it is believed to help koronaviruspandemiaan.

Markku Jalkanen, CEO of Faron Pharmaceuticals Oy, tells MTV News that it is not possible to talk about the drug yet, but Traumakine is currently the name of the project.

“We don't have a drug yet, but a clinical study that regulates the expression of the CD73 molecule, which is involved in maintaining lung capillaries. What always works is the human peptide hormone interferon beta, which is also induced by all viral infections in response to limiting viral infection, Jalkanen says.
[Image: BB11xHa3.img?h=240&w=255&m=6&q=60&o=f&l=f&x=139&y=135]© Edku Markku Jalkanen, Managing Director of MTV Faron Pharmaceuticals Oy, says that Traumaquinea has been developed for over 10 years. Photo: Faron Pharmaceuticals Oy
According to Jalkanen, the regulation of the CD73 molecule is particularly important in the lungs, where gas exchange takes place in the capillaries. If gases leak into the lungs, severe pulmonary insufficiency occurs. Coronary patients die of this condition and are commonly referred to as acute respiratory distress syndrome (ARDS). 

[Image: 5e76420ee4b0ba35a9ad3050-1584808990278?l...height=534]

The first coronavirus death did not surprise authorities - in a direct interview with THL's CEO
MTV News Live
7 min

Video Player from: MTV ( [url=]Privacy Policy )

- Traumaquin is intended to prevent or limit the development or progression of ARDS by restoring capillary integrity.

Further research is needed

Traumatic development work has been ongoing for more than a decade and has included a number of clinical trials around the world.

The marketing of the finished medicinal product to the Finnish market, ie the marketing authorization, is subject to regulatory approval through clinical trials and is not available until further investigation. Jalkanen estimates that it will take 2-3 years to obtain a marketing authorization. In theory, Traumakine can also be introduced on an accelerated schedule, but it requires the permission of the Finnish Medicines Agency, Fimea.

According to Jalkanen, the risks associated with the substance are lower than normal, because our own body produces the same substance anyway, but not necessarily enough. Previous drug trials have realized the high risk associated with duplicate use of corticosteroids, which in turn prevented the effect of Trauma.

- This error will be corrected in the following studies, which do not allow their duplication, Jalkanen adds.

Forum Jump:

Users browsing this thread: 1 Guest(s)